Representatives of Breast Cancer Aotearoa Coalition (BCAC) went to Wellington recently to meet with Government and National MPs who have health responsibilities to discuss some of the key issues af
Important research released 21 June shows huge disparities in breast cancer screening, treatment and outcomes for Māori and Pasifika women in New Zealand.
BCAC says a new report highlights how desperately poor access to new and innovative medicines is in New Zealand.
BCAC committee member, Louise Malone, attended the San Antonio Breast Cancer Symposium in December 2017 and gives us an update on the latest cutting-edge research into new targeted immunoth
The Breast Cancer Aotearoa Coalition (BCAC) is pushing for the chemotherapy drug, Abraxane, to be publicly funded for women with advanced breast cancer.
Metavivors NZ members were in full force at BCAC’s Annual General Meeting at Domain Lodge in Auckland recently.
BCAC is pushing for breakthrough breast cancer drug, Kadcyla, to be publicly funded in New Zealand after a “monumental u-turn” in the UK which has seen the drug funded there.
New guidelines in the UK recommend that healthy post-menopausal women with a familial risk of developing breast cancer be prescribed the medicine anastrazole in a bid to help ward off the disease.<
Two of the country’s major breast cancer charities have joined forces to plead for the 160 women denied public access to the breakthrough breast cancer drug, Perjeta.
The latest in new and innovative breast cancer treatments and recent developments to empower patients were discussed at the Australia New Zealand Breast Cancer Clinical Trials Group (ANZBCTG) confe
